AntibioticDB

Development status: Discontinued

Gram-positive activity

Propensity to select resistant bacteria

Mechanism of Action/Target pathogen: Inhibits bacterial DNA gyrase via binding to the ATP-binding site of the GyrB subunit of the enzyme. Novobiocin acts as competitive inhibitor of the ATPase reaction; active mainly against Gram-positive bacteria.

Reason dropped: Terminated due to toxicity

Additional information: Streptomyces natural product

GtoPDB link: https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=12021

Source: https://pubmed.ncbi.nlm.nih.gov/13273516/

Citation (1): https://pubmed.ncbi.nlm.nih.gov/29746111/

Citation (2): https://pubmed.ncbi.nlm.nih.gov/2591171/

Citation (3): https://pubmed.ncbi.nlm.nih.gov/28019639/

Compound/Drug Structure: https://pubchem.ncbi.nlm.nih.gov/compound/54675769

Novobiocin

Aminocoumarin

1955